QRG Capital Management Inc. Has $100.89 Million Holdings in Eli Lilly and Company $LLY

QRG Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 129,427 shares of the company’s stock after buying an additional 3,202 shares during the period. Eli Lilly and Company comprises 0.9% of QRG Capital Management Inc.’s holdings, making the stock its 15th largest position. QRG Capital Management Inc.’s holdings in Eli Lilly and Company were worth $100,892,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. Successful Portfolios LLC increased its position in shares of Eli Lilly and Company by 2.5% in the second quarter. Successful Portfolios LLC now owns 1,301 shares of the company’s stock valued at $1,014,000 after acquiring an additional 32 shares during the last quarter. Grassi Investment Management increased its position in shares of Eli Lilly and Company by 0.3% in the second quarter. Grassi Investment Management now owns 79,927 shares of the company’s stock valued at $62,305,000 after acquiring an additional 200 shares during the last quarter. Corundum Group Inc. increased its position in shares of Eli Lilly and Company by 55.9% in the second quarter. Corundum Group Inc. now owns 1,629 shares of the company’s stock valued at $1,270,000 after acquiring an additional 584 shares during the last quarter. Segment Wealth Management LLC increased its position in shares of Eli Lilly and Company by 221.7% in the second quarter. Segment Wealth Management LLC now owns 4,452 shares of the company’s stock valued at $3,470,000 after acquiring an additional 3,068 shares during the last quarter. Finally, Fortis Capital Advisors LLC increased its position in shares of Eli Lilly and Company by 2.1% in the second quarter. Fortis Capital Advisors LLC now owns 1,771 shares of the company’s stock valued at $1,381,000 after acquiring an additional 37 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jamere Jackson purchased 200 shares of the stock in a transaction on Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on LLY shares. Morgan Stanley lowered their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a report on Sunday, August 17th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Saturday, September 27th. Finally, UBS Group dropped their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $933.39.

Eli Lilly and Company Stock Up 2.5%

Eli Lilly and Company stock opened at $840.46 on Friday. The stock has a market cap of $795.47 billion, a P/E ratio of 54.93, a P/E/G ratio of 1.14 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company’s 50-day moving average price is $734.60 and its two-hundred day moving average price is $766.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.